Y Intercept Hong Kong Ltd Purchases Shares of 42,975 Surmodics, Inc. $SRDX

Y Intercept Hong Kong Ltd purchased a new stake in Surmodics, Inc. (NASDAQ:SRDX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 42,975 shares of the company’s stock, valued at approximately $1,277,000.

Several other large investors have also recently added to or reduced their stakes in SRDX. Strs Ohio acquired a new position in Surmodics in the 1st quarter valued at approximately $122,000. AlphaQuest LLC acquired a new position in Surmodics in the 1st quarter valued at approximately $232,000. Inspire Investing LLC raised its holdings in Surmodics by 11.3% in the 1st quarter. Inspire Investing LLC now owns 11,250 shares of the company’s stock valued at $343,000 after acquiring an additional 1,142 shares in the last quarter. Invesco Ltd. raised its holdings in Surmodics by 103.9% in the 1st quarter. Invesco Ltd. now owns 11,844 shares of the company’s stock valued at $362,000 after acquiring an additional 6,036 shares in the last quarter. Finally, Maven Securities LTD acquired a new position in Surmodics in the 1st quarter valued at approximately $366,000. Institutional investors and hedge funds own 96.63% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on SRDX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surmodics in a report on Wednesday, October 8th. Barrington Research reissued a “market perform” rating on shares of Surmodics in a report on Monday, August 11th. Finally, Zacks Research raised Surmodics to a “hold” rating in a report on Tuesday, August 12th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $43.00.

Surmodics Trading Up 1.0%

Shares of SRDX opened at $27.43 on Monday. Surmodics, Inc. has a 1 year low of $26.00 and a 1 year high of $40.38. The company has a current ratio of 3.91, a quick ratio of 3.10 and a debt-to-equity ratio of 0.27. The stock has a 50 day simple moving average of $30.51 and a 200-day simple moving average of $30.80. The stock has a market cap of $392.19 million, a PE ratio of -22.30 and a beta of 1.31.

Surmodics (NASDAQ:SRDX) last issued its earnings results on Friday, August 8th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.27. Surmodics had a negative return on equity of 2.99% and a negative net margin of 14.59%.The business had revenue of $29.57 million during the quarter, compared to analysts’ expectations of $28.04 million. Surmodics has set its FY 2025 guidance at -0.350–0.200 EPS. On average, sell-side analysts predict that Surmodics, Inc. will post 0.2 EPS for the current fiscal year.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).